Table 2.
Projected outcomes of six TB screening strategies for a cohort of 1000 healthcare workers over 20 years: base-case scenario
| Strategy | Cost in 2015 $CAN | QALYs | New active TB cases | Deaths due to active TB | Deaths due to adverse event to treatment of active TB | Deaths due to adverse event to treatment of LTBI | True positive results | False positive results |
|---|---|---|---|---|---|---|---|---|
| Post-exposure screening only | ||||||||
| Tuberculin Skin Test | $66,387 | 15,239.98 | 3.03 | 0.13 | 0.0023 | 0.00036 | 63 | 6 |
| QuantiFERON®-TB-Gold | $77,521 | 15,239.85 | 2.97 | 0.13 | 0.0023 | 0.00040 | 67 | 11 |
| Targeted screening | ||||||||
| Tuberculin Skin Test | $151,517 | 15,237.96 | 2.83 | 0.12 | 0.0022 | 0.00093 | 67 | 109 |
| QuantiFERON®-TB-Gold | $263,660 | 15,236.90 | 2.86 | 0.13 | 0.0022 | 0.00120 | 63 | 161 |
| Annual screening | ||||||||
| Tuberculin Skin Test | $404,956 | 15,231.85 | 2.68 | 0.12 | 0.0020 | 0.00258 | 75 | 413 |
| QuantiFERON®-TB-Gold | $817,695 | 15,227.92 | 2.80 | 0.12 | 0.0021 | 0.00362 | 64 | 607 |
TB tuberculosis, QALYs quality-adjusted life years, LTBI latent tuberculosis infection